Stifel raised the firm’s price target on Ligand (LGND) to $230 from $220 and keeps a Buy rating on the shares after an investor day that the firm says covered “key growth drivers within its diverse royalty portfolio as well as recent value-creating transactions” that will support achieving the raised five-year royalty compound annual growth rate of greater than 23%.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND: